Strategic merger Stelis Biopharma recently merged with SteriScience and Strides to form OneSource Specialty, signaling a strengthened CDMO platform and expanded scale. This creates cross-sell opportunities across a larger integrated biopharma services footprint and potential access to a broader client base seeking end-to-end biologics development and manufacturing.

Integrated capability As a fully integrated CDMO offering cell line and process development through to fill/finish, Stelis can target biopharma companies in need of a single vendor for end-to-end biologics programs, reducing vendor management complexity and timelines for drug substances and drug products.

Bengaluru footprint Located in Bengaluru, India, Stelis leverages a tech-enabled hub with scale-up and cGMP manufacturing facilities. This positions the company to attract biotech and global partners seeking cost-efficient production with access to emerging-market innovation and supply chain resilience.

Strategic partnerships Past and ongoing partnerships with Syngene and Synoptics, plus the large merger creating OneSource, indicate a readiness to pursue co-development, contract manufacturing, and collaboration deals. Sales teams can pursue joint-venture or co-development opportunities with these aligned entities.

Funding & growth With a Series C funding of $125M historically and current revenue in the mid-range for a CDMO, Stelis shows growth capability and investor backing. This supports pursuing multi-program engagements, multi-site programs, and scalable manufacturing deals for biologics and complex molecules.